2m 2m 2m 2m 2m 2m 2m
ALIGOS THERAPT (ALGS)
NASDAQ
$5.12-$0.02 (-0.39%)
Price as of Jun 03, 2026 7:27 PM EDT- $30.7MMarket Cap
- -11.76%1-Year Change
- BiotechnologyIndustry
ALIGOS THERAPT (ALGS)
$5.12-$0.02 (-0.39%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 2.2M -39.46% | 3.6M -41.67% | 6.2M -55.48% | 13.9M +219.04% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 2.2M -39.46% | 3.6M -41.67% | 6.2M -55.48% | 13.9M +219.04% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -69.5M -1.16% | -70.3M -3.79% | -73.0M -14.15% | -85.1M -18.32% | |
Depreciation and Amortization Expense | 930,000 -9.44% | 1.0M -34.12% | 1.6M -32.39% | 2.3M -23.62% | |
Total Operating Expenses | 90.2M -3.15% | 93.1M -10.18% | 103.7M -7.02% | 111.5M -15.97% | |
Operating Profit | -88.0M -1.31% | -89.2M +1.17% | -88.1M -9.69% | -97.6M -23.96% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 2.2M +29.41% | 1.7M -60.47% | 4.3M +186.67% | 1.5M +650.00% | |
Income before Taxes | -23.9M -81.76% | -130.9M +50.64% | -86.9M -9.44% | -95.9M -25.16% | |
Income Taxes | 314,000 -5.14% | 331,000 -58.36% | 795,000 +650.00% | 106,000 -25.87% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -24.2M -81.56% | -131.2M +49.65% | -87.7M -8.71% | -96.0M -25.16% | |
Net Income from Continuing Operations Applicable to Common | -23.9M -81.76% | -130.9M +50.64% | -86.9M -9.44% | -95.9M -25.16% | |
Basic EPS and Net Income | -2.45 -88.30% | -20.94 +1,439.71% | -1.36 -39.56% | -2.25 -30.12% | |
Diluted EPS and Net Income | -2.45 -88.30% | -20.94 +1,439.71% | -1.36 -39.56% | -2.25 -30.12% | |
Basic Weighted Average Shares | 9.9M +57.79% | 6.3M -90.25% | 64.3M +50.51% | 42.7M +7.13% | |
Diluted Weighted Average Shares | 9.9M +57.79% | 6.3M -90.25% | 64.3M +50.51% | 42.7M +7.13% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 18.3M -50.53% | 37.0M -72.74% | 135.7M +66.82% | 81.3M -56.46% | |
Short-Term Investments | 59.5M +198.57% | 19.9M -55.17% | 44.5M 0.00% | 44.5M +1,035.27% | |
Cash and Cash Equivalents and Short-Term Investments | 77.8M +36.71% | 56.9M -68.40% | 180.2M +43.20% | 125.8M -34.03% | |
Total Current Assets | 82.9M +33.35% | 62.1M -55.95% | 141.1M +5.65% | 133.5M -34.67% | |
Accumulated Depreciation | 12.7M +7.89% | 11.8M +9.55% | 10.8M +12.41% | 9.6M +31.75% | |
Property and Plant and Equipment and Net | 1.9M -20.96% | 2.4M -27.52% | 3.3M -32.33% | 4.8M -22.07% | |
Total Long-Term Assets | 715,000 +14.04% | 627,000 +0.32% | 625,000 -1.42% | 634,000 -26.79% | |
Total Assets | 88.5M +26.31% | 70.1M -53.74% | 151.5M +3.30% | 146.7M -37.68% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 21.2M -2.32% | 21.7M -9.07% | 23.9M -27.84% | 33.1M -14.96% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 1.5M -68.20% | 4.8M -37.47% | 7.7M -16.66% | 9.2M -18.48% | |
Total Liabilities | 35.0M -64.68% | 99.1M +66.65% | 59.4M +38.92% | 42.8M -15.49% | |
Retained Earnings | -642.2M +3.91% | -618.0M +26.95% | -486.8M +21.97% | -399.1M +31.69% | |
Total Stockholders Equity | 53.5M +284.81% | -29.0M -131.47% | 92.1M -11.38% | 103.9M -43.76% | |
Total Shares Outstanding | 6.2M +59.87% | 3.9M -94.85% | 75.1M +74.96% | 42.9M +0.55% | |
Cash Flow | |||||
Cash from Operating Activities | -82.5M +2.18% | -80.7M +2.21% | -79.0M -0.49% | -79.4M -31.36% | |
Capital Expenditures | N/A N/A | 130,000 +584.21% | 19,000 -97.99% | 943,000 +5.72% | |
Cash from Investing Activities | -37.8M +106.94% | -18.3M -140.64% | 45.0M +271.08% | -26.3M -970.05% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 101.6M +28,529.58% | 355,000 -99.60% | 88.3M +53,758.54% | 164,000 -99.79% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -4,024.93% +63.02% | -2,468.96% +73.45% | -1,423.47% +102.87% | -701.66% -76.16% | |
Return on Assets | -30.50% -74.24% | -118.41% +101.37% | -58.80% +16.95% | -50.28% -1.92% | |
Return on Equity | -196.92% -52.65% | -415.84% +364.74% | -89.48% +34.45% | -66.55% +4.96% | |
Revenue Growth | -39.46% -5.30% | -41.67% -24.89% | -55.48% -125.33% | 219.04% -16.79% | |
Current Ratio | 3.90 +36.51% | 2.86 -51.56% | 5.90 +46.40% | 4.03 -23.18% | |
Cash Ratio | 0.86 -49.35% | 1.70 -70.02% | 5.68 +131.18% | 2.46 -48.79% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow